BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 36210836)

  • 21. A comprehensive analysis and validation of cuproptosis-associated genes across cancers: Overall survival, the tumor microenvironment, stemness scores, and drug sensitivity.
    Liu J; Lu Y; Dai Y; Shen Y; Zeng C; Liu X; Yu H; Deng J; Lu W
    Front Genet; 2022; 13():939956. PubMed ID: 36105090
    [No Abstract]   [Full Text] [Related]  

  • 22. Cuproptosis-related gene FDX1 as a prognostic biomarker for kidney renal clear cell carcinoma correlates with immune checkpoints and immune cell infiltration.
    Yao Y; Chen H; Lou M; Chen T
    Front Genet; 2023; 14():1071694. PubMed ID: 36755576
    [No Abstract]   [Full Text] [Related]  

  • 23. FDX1 expression predicts favourable prognosis in clear cell renal cell carcinoma identified by bioinformatics and tissue microarray analysis.
    Huang X; Wang T; Ye J; Feng H; Zhang X; Ma X; Wang B; Huang Y; Zhang X
    Front Genet; 2022; 13():994741. PubMed ID: 36186457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer.
    Huang D; Shen J; Zhai L; Chen H; Fei J; Zhu X; Zhou J
    Front Immunol; 2021; 12():812713. PubMed ID: 35069601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Confirmation of the predictive function of cuproptosis-related gene FDX1 in clear cell renal carcinoma using qRT-PCR and western blotting.
    Cai C; Zhou K; Jing J; Ren Y; Weng G; Cen D; Wang X; Huang S
    Aging (Albany NY); 2023 Jul; 15(13):6117-6134. PubMed ID: 37432054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic, Clinicopathological, and Function of Key Cuproptosis Regulator
    Zeng S; Zhang H; Zhang D; Hu X; Song L
    Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrated profiling identifies ferredoxin 1 as an immune-related biomarker of malignant phenotype in glioma.
    Xie D; Huang H; Guo Y; Jiang Z; Kuang Y; Huang H; Liu W; Wang L; Xin Z; Wang B; Ren C; Jiang X
    Heliyon; 2024 Mar; 10(5):e26976. PubMed ID: 38463788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Integrated Analysis Identified TAGLN2 As an Oncogene Indicator Related to Prognosis and Immunity in Pan-Cancer.
    Pan T; Wang S; Wang Z
    J Cancer; 2023; 14(10):1809-1836. PubMed ID: 37476180
    [No Abstract]   [Full Text] [Related]  

  • 29. A Pan-Cancer Analysis of the Oncogenic Role of
    Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
    Front Genet; 2022; 13():906174. PubMed ID: 35910232
    [No Abstract]   [Full Text] [Related]  

  • 30. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
    Zhang J; Wang K; Hainisayimu T; Li H
    Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pan-Cancer Analysis of the N6-Methyladenosine Eraser FTO as a Potential Prognostic and Immunological Biomarker.
    Zhao C; Liu Y; Ju S; Wang X
    Int J Gen Med; 2021; 14():7411-7422. PubMed ID: 34744452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
    Wu Y; Huang W; Xie Y; Wang C; Luo N; Chen Y; Wang L; Cheng Z; Gao Z; Liu S
    Front Mol Biosci; 2022; 9():743515. PubMed ID: 35372497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis.
    Liu P; Wang X; Pan L; Han B; He Z
    Front Immunol; 2022; 13():901784. PubMed ID: 35720327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation, genomics, and clinical characteristics of cuproptosis regulators in pan-cancer.
    Zhou C; Li C; Zheng Y; Huang X
    Front Oncol; 2022; 12():934076. PubMed ID: 36387247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LINC02362/hsa-miR-18a-5p/FDX1 axis suppresses proliferation and drives cuproptosis and oxaliplatin sensitivity of hepatocellular carcinoma.
    Quan B; Liu W; Yao F; Li M; Tang B; Li J; Ren Z; Yin X
    Am J Cancer Res; 2023; 13(11):5590-5609. PubMed ID: 38058825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SERPINH1 is a Potential Prognostic Biomarker and Correlated With Immune Infiltration: A Pan-Cancer Analysis.
    Wang Y; Gu W; Wen W; Zhang X
    Front Genet; 2021; 12():756094. PubMed ID: 35058967
    [No Abstract]   [Full Text] [Related]  

  • 37. Integrated analyses reveal the prognostic, immunological features and mechanisms of cuproptosis critical mediator gene FDX1 in KIRC.
    Wang Y; Zhang X; Chen G; Xing Q; Zhu B; Wang X
    Genes Immun; 2023 Aug; 24(4):171-182. PubMed ID: 37430022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune Infiltration of MMP14 in Pan Cancer and Its Prognostic Effect on Tumors.
    Li M; Li S; Zhou L; Yang L; Wu X; Tang B; Xie S; Fang L; Zheng S; Hong T
    Front Oncol; 2021; 11():717606. PubMed ID: 34604053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic pan-cancer analysis identifies
    Chen P; Yang X; Wang P; He H; Chen Y; Yu L; Fang H; Wang F; Huang Z
    Ann Transl Med; 2023 Jan; 11(2):121. PubMed ID: 36819495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
    Chen Y
    Front Genet; 2022; 13():912037. PubMed ID: 35937995
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.